Tumor promoting effect of PDLIM2 downregulation involves mitochondrial ROS, oncometabolite accumulations and HIF-1α activation DOI Creative Commons
Jingxing Yang,

Yu-Chen Chuang,

Jen‐Chih Tseng

и другие.

Journal of Experimental & Clinical Cancer Research, Год журнала: 2024, Номер 43(1)

Опубликована: Июнь 17, 2024

Abstract Background Cancer is characterized by dysregulated cellular metabolism. Thus, understanding the mechanisms underlying these metabolic alterations important for developing targeted therapies. In this study, we investigated pro-tumoral effect of PDZ and LIM domain 2 (PDLIM2) downregulation in lung cancer growth its association with accumulation mitochondrial ROS, oncometabolites activation hypoxia-inducible factor-1 (HIF-1) α process. Methods Databases human tissue samples were analyzed to investigate roles PDLIM2 HIF-1α growth. DNA microarray gene ontology enrichment analyses performed determine functions PDLIM2. Seahorse assay, flow cytometric analysis, confocal microscopic analysis employed study functions. Oncometabolites using liquid chromatography–mass spectrometry (LC–MS). A Lewis carcinoma (LLC) mouse model was established assess vivo function HIF-1α. Results The expression downregulated cancer, correlated poor prognosis patients. highly regulated genes associated Mechanistically, resulted NF-κB activation, impaired tricarboxylic acid (TCA) cycle particularly succinate dehydrogenase (SDH) genes, dysfunction. This disturbance contributed other oncometabolites, as well buildup reactive oxygen species (mtROS), leading factor 1α (HIF-1α). Furthermore, increased all stages cancer. reversely animal orally administered inhibitor, PX-478, significantly reduces knockdown-promoted tumor Conclusion These findings shed light on complex action mitochondria activities emphasizing role tumor-promoting downregulation. Additionally, they provide new insights into a strategy precise treatment suggesting that inhibitors may serve therapy patients

Язык: Английский

Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges DOI Creative Commons

Yuchu Xiang,

Xudong Liu, Yifan Wang

и другие.

Frontiers in Immunology, Год журнала: 2024, Номер 15

Опубликована: Апрель 9, 2024

Resistance to targeted therapy and immunotherapy in non-small cell lung cancer (NSCLC) is a significant challenge the treatment of this disease. The mechanisms resistance are multifactorial include molecular target alterations activation alternative pathways, tumor heterogeneity microenvironment change, immune evasion, immunosuppression. Promising strategies for overcoming development combination therapies, understanding better use novel drug targets, identification biomarkers, modulation so on. Ongoing research into new therapeutic approaches hold great promise improving outcomes patients with NSCLC. Here, we summarize diverse driving NSCLC latest potential promising overcome help who suffer from

Язык: Английский

Процитировано

27
Tumor microenvironment: recent advances in understanding and its role in modulating cancer therapies DOI
Disha D. Shah, Mehul R. Chorawala, Neha R. Raghani

и другие.

Medical Oncology, Год журнала: 2025, Номер 42(4)

Опубликована: Март 18, 2025

Язык: Английский

Процитировано

4
Nanomedicine Combats Drug Resistance in Lung Cancer DOI
Xiuli Zheng, Xiao-Hai Song,

Guonian Zhu

и другие.

Advanced Materials, Год журнала: 2023, Номер 36(3)

Опубликована: Ноя. 16, 2023

Lung cancer is the second most prevalent and leading cause of cancer-related death worldwide. Surgery, chemotherapy, molecular targeted therapy, immunotherapy, radiotherapy are currently available as treatment methods. However, drug resistance a significant factor in failure lung treatments. Novel therapeutics have been exploited to address complicated mechanisms advancement nanomedicine extremely promising terms overcoming resistance. Nanomedicine equipped with multifunctional tunable physiochemical properties alignment tumor genetic profiles can achieve precise, safe, effective while minimizing or eradicating cancer. Here, this work reviews discovered for radiotherapy, outlines novel strategies development against This focuses on engineering design, customized delivery, current challenges, clinical translation application resistant

Язык: Английский

Процитировано

39
Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions DOI Open Access
Pankaj Garg, Sulabh Singhal, Prakash Kulkarni

и другие.

Journal of Clinical Medicine, Год журнала: 2024, Номер 13(14), С. 4189 - 4189

Опубликована: Июль 18, 2024

The leading cause of cancer deaths worldwide is attributed to non-small cell lung (NSCLC), necessitating a continual focus on improving the diagnosis and treatment this disease. In review, latest breakthroughs emerging trends in managing NSCLC are highlighted. Major advancements diagnostic methods, including better imaging technologies utilization molecular biomarkers, discussed. These have greatly enhanced early detection personalized plans. Significant improvements patient outcomes been achieved by new targeted therapies immunotherapies, providing hope for individuals with advanced NSCLC. This review discusses persistent challenges accessing treatments their associated costs despite recent progress. Promising research into therapies, such as CAR-T therapy oncolytic viruses, which could further revolutionize treatment, also aims inform inspire continued efforts improve patients globally, offering comprehensive overview current state future possibilities.

Язык: Английский

Процитировано

14
Nanozymes with biomimetically designed properties for cancer treatment DOI Creative Commons
Ke Xu, Yujie Cui, Bin Guan

и другие.

Nanoscale, Год журнала: 2024, Номер 16(16), С. 7786 - 7824

Опубликована: Янв. 1, 2024

The therapeutic efficacy of nanozymes, which have wide applications in cancer treatment, can be enhanced by various biomimetic design strategies, from structural and process mimicry to advanced functional biomimicry.

Язык: Английский

Процитировано

11
PPARγ Modulators in Lung Cancer: Molecular Mechanisms, Clinical Prospects, and Challenges DOI Creative Commons
Jiyun Zhang,

Miru Tang,

Jinsai Shang

и другие.

Biomolecules, Год журнала: 2024, Номер 14(2), С. 190 - 190

Опубликована: Фев. 4, 2024

Lung cancer is one of the most lethal malignancies worldwide. Peroxisome proliferator-activated receptor gamma (PPARγ, NR1C3) a ligand-activated transcriptional factor that governs expression genes involved in glucolipid metabolism, energy homeostasis, cell differentiation, and inflammation. Multiple studies have demonstrated PPARγ activation exerts anti-tumor effects lung through regulation lipid induction apoptosis, cycle arrest, as well inhibition invasion migration. Interestingly, may pro-tumor on cells tumor microenvironment, especially myeloid cells. Recent clinical data has substantiated potential agonists therapeutic agents for cancer. Additionally, also show synergistic with traditional chemotherapy radiotherapy. However, application remains limited due to presence adverse side effects. Thus, further research trials are necessary comprehensively explore actions both stromal evaluate vivo toxicity. This review aims consolidate molecular mechanism modulators discuss their prospects challenges tackling

Язык: Английский

Процитировано

10
Targeting KRAS-G12C in Lung Cancer: The Emerging Role of PROTACs in Overcoming Resistance DOI

Kumarappan Chidambaram,

Arcot Rekha, Ahsas Goyal

и другие.

Pathology - Research and Practice, Год журнала: 2025, Номер unknown, С. 155954 - 155954

Опубликована: Апрель 1, 2025

Язык: Английский

Процитировано

1
Activities against Lung Cancer of Biosynthesized Silver Nanoparticles: A Review DOI Creative Commons
Jorge L. Mejía-Méndez, Edgar R. López-Mena, Eugenio Sánchez-Arreola

и другие.

Biomedicines, Год журнала: 2023, Номер 11(2), С. 389 - 389

Опубликована: Янв. 28, 2023

Nanomedicine is an interdisciplinary field where nanostructured objects are applied to treat or diagnose disease. Nanoparticles (NPs) a special class of materials at nanometric scale that can be prepared from lipids, polymers, noble metals through bottom-up approaches. Biological synthesis reliable, sustainable, and non-toxic method uses phytochemicals, microorganisms, enzymes induce the reduction metal ions into NPs. Silver (Ag) NPs exhibit potent therapeutic properties exploited overcome limitations current treatment modalities for human health issues such as lung cancer (LC). Here, we review preparation AgNPs using biological their application against LC in vitro vivo models. An overview staging, diagnosis, genetic mutations, LC, well its main subtypes, presented. A summary reaction mechanisms microbial cell cultures, plant extracts, amino acids included. The use capping agents biosynthesis with anticancer activity also detailed. history activities metal-based nanostructures synthesized gold, copper, palladium, platinum considered. possible models covered. Our perspective about future nanomedicine added.

Язык: Английский

Процитировано

23
Overcoming Cancer Resistance: Strategies and Modalities for Effective Treatment DOI Creative Commons
Mahesh Koirala,

Mario DiPaola

Biomedicines, Год журнала: 2024, Номер 12(8), С. 1801 - 1801

Опубликована: Авг. 8, 2024

Resistance to cancer drugs is a complex phenomenon that poses significant challenge in the treatment of various malignancies. This review comprehensively explores resistance mechanisms and discusses emerging strategies modalities overcome this obstacle. Many factors contribute resistance, including genetic mutations, activation alternative signaling pathways, alterations tumor microenvironment. Innovative approaches, such as targeted protein degradation, immunotherapy combinations, precision medicine, novel drug delivery systems, hold promise for improving outcomes. Understanding intricacies leveraging innovative are essential advancing therapy.

Язык: Английский

Процитировано

9
Social and Biological Determinants in Lung Cancer Disparity DOI Open Access
Briana A. Brock, Hina Mir,

Eric L. Flenaugh

и другие.

Cancers, Год журнала: 2024, Номер 16(3), С. 612 - 612

Опубликована: Янв. 31, 2024

Lung cancer remains a leading cause of death in the United States and globally, despite progress treatment screening efforts. While mortality rates have decreased recent years, long-term survival patients with lung continues to be challenge. Notably, African American (AA) men experience significant disparities compared European Americans (EA) terms incidence, treatment, survival. Previous studies explored factors such as smoking patterns complex social determinants, including socioeconomic status, personal beliefs, systemic racism, indicating their role these disparities. In addition factors, emerging evidence points variations tumor biology, immunity, comorbid conditions contributing racial this disease. This review emphasizes differences patterns, screening, early detection intricate interplay social, biological, environmental that make more susceptible developing experiencing poorer outcomes.

Язык: Английский

Процитировано

7